BenevolentAI has announced that it will be collaborating with the UK-based Pharma company AstraZeneca. The collaboration will see the application of artificial intelligence for drug discovery and development of new treatments.
The collaboration will lay special emphasis on using AI to discover drugs and develop treatments for chronic kidney disease and idiopathic pulmonary fibrosis. These diseases have a biology which has not been understood well until now. By combining AstraZeneca’s disease area expertise with BenevolentAI’s leading AI, the companies are looking to unlock the potential of data which will help them understand complex disease biology and find new ways to tackle these diseases.
“Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis,” said Joanna Shields, CEO of BenevolentAI.
Global Market Insights believes that the Healthcare Artificial Intelligence Market is expected to see 41.7% CAGR from 2019 to 2025, so the collaboration between the two companies comes at the right time.
AirAsia collaborating with Google Cloud to provide digital skills training in Malaysia
MediaTek and Intel are collaborating for 5G laptops
AI startup gives out resources to global drug firms for free
DeepMind is collaborating with Ecologists and Conservationists
Antibiotics on Its Types, Drug Interactions, and Side Effects
© 2020 CIO Bulletin. All rights reserved.